Impaired proteostatic mechanisms other than decreased protein synthesis limit old skeletal muscle recovery after disuse atrophy.
collagen
isotope labelling
protein aggregates
protein turnover
proteomics
ribosome biogenesis
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
10
04
2023
received:
03
02
2023
accepted:
22
05
2023
medline:
23
10
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
Skeletal muscle mass and strength diminish during periods of disuse but recover upon return to weight bearing in healthy adults but are incomplete in old muscle. Efforts to improve muscle recovery in older individuals commonly aim at increasing myofibrillar protein synthesis via mammalian target of rapamycin (mTOR) stimulation despite evidence demonstrating that old muscle has chronically elevated levels of mammalian target of rapamycin complex 1 (mTORC1) activity. We hypothesized that protein synthesis is higher in old muscle than adult muscle, which contributes to a proteostatic stress that impairs recovery. We unloaded hindlimbs of adult (10-month) and old (28-month) F344BN rats for 14 days to induce atrophy, followed by reloading up to 60 days with deuterium oxide (D We found that old muscle has limited recovery of muscle mass during reloading despite having higher translational capacity and myofibrillar protein synthesis (0.029 k/day ± 0.002 vs. 0.039 k/day ± 0.002, P < 0.0001) than adult muscle. We showed that collagen protein synthesis was not different (0.005 k (1/day) ± 0.0005 vs. 0.004 k (1/day) ± 0.0005, P = 0.15) in old compared to adult, but old muscle had higher collagen concentration (4.5 μg/mg ± 1.2 vs. 9.8 μg/mg ± 0.96, P < 0.01), implying that collagen breakdown was slower in old muscle than adult muscle. This finding was supported by old muscle having more insoluble collagen (4.0 ± 1.1 vs. 9.2 ± 0.9, P < 0.01) and an accumulation of advanced glycation end products (1.0 ± 0.06 vs. 1.5 ± 0.08, P < 0.001) than adult muscle during reloading. Limited recovery of muscle mass during reloading is in part due to higher protein degradation (0.017 1/t ± 0.002 vs. 0.028 1/t ± 0.004, P < 0.05) and/or compromised proteostasis as evidenced by accumulation of ubiquitinated insoluble proteins (1.02 ± 0.06 vs. 1.22 ± 0.06, P < 0.05). Last, we showed that synthesis of individual proteins related to protein folding/refolding, protein degradation and neural-related biological processes was higher in old muscle during reloading than adult muscle. Our data suggest that the failure of old muscle to recover after disuse is not due to limitations in the ability to synthesize myofibrillar proteins but because of other impaired proteostatic mechanisms (e.g., protein folding and degradation). These data provide novel information on individual proteins that accumulate in protein aggregates after disuse and certain biological processes such as protein folding and degradation that likely play a role in impaired recovery. Therefore, interventions to enhance regrowth of old muscle after disuse should be directed towards the identified impaired proteostatic mechanisms and not aimed at increasing protein synthesis.
Sections du résumé
BACKGROUND
Skeletal muscle mass and strength diminish during periods of disuse but recover upon return to weight bearing in healthy adults but are incomplete in old muscle. Efforts to improve muscle recovery in older individuals commonly aim at increasing myofibrillar protein synthesis via mammalian target of rapamycin (mTOR) stimulation despite evidence demonstrating that old muscle has chronically elevated levels of mammalian target of rapamycin complex 1 (mTORC1) activity. We hypothesized that protein synthesis is higher in old muscle than adult muscle, which contributes to a proteostatic stress that impairs recovery.
METHODS
We unloaded hindlimbs of adult (10-month) and old (28-month) F344BN rats for 14 days to induce atrophy, followed by reloading up to 60 days with deuterium oxide (D
RESULTS
We found that old muscle has limited recovery of muscle mass during reloading despite having higher translational capacity and myofibrillar protein synthesis (0.029 k/day ± 0.002 vs. 0.039 k/day ± 0.002, P < 0.0001) than adult muscle. We showed that collagen protein synthesis was not different (0.005 k (1/day) ± 0.0005 vs. 0.004 k (1/day) ± 0.0005, P = 0.15) in old compared to adult, but old muscle had higher collagen concentration (4.5 μg/mg ± 1.2 vs. 9.8 μg/mg ± 0.96, P < 0.01), implying that collagen breakdown was slower in old muscle than adult muscle. This finding was supported by old muscle having more insoluble collagen (4.0 ± 1.1 vs. 9.2 ± 0.9, P < 0.01) and an accumulation of advanced glycation end products (1.0 ± 0.06 vs. 1.5 ± 0.08, P < 0.001) than adult muscle during reloading. Limited recovery of muscle mass during reloading is in part due to higher protein degradation (0.017 1/t ± 0.002 vs. 0.028 1/t ± 0.004, P < 0.05) and/or compromised proteostasis as evidenced by accumulation of ubiquitinated insoluble proteins (1.02 ± 0.06 vs. 1.22 ± 0.06, P < 0.05). Last, we showed that synthesis of individual proteins related to protein folding/refolding, protein degradation and neural-related biological processes was higher in old muscle during reloading than adult muscle.
CONCLUSIONS
Our data suggest that the failure of old muscle to recover after disuse is not due to limitations in the ability to synthesize myofibrillar proteins but because of other impaired proteostatic mechanisms (e.g., protein folding and degradation). These data provide novel information on individual proteins that accumulate in protein aggregates after disuse and certain biological processes such as protein folding and degradation that likely play a role in impaired recovery. Therefore, interventions to enhance regrowth of old muscle after disuse should be directed towards the identified impaired proteostatic mechanisms and not aimed at increasing protein synthesis.
Identifiants
pubmed: 37448295
doi: 10.1002/jcsm.13285
pmc: PMC10570113
doi:
Substances chimiques
TOR Serine-Threonine Kinases
EC 2.7.11.1
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2076-2089Subventions
Organisme : NCCIH NIH HHS
ID : R13 AT011473
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG052363
Pays : United States
Organisme : NCCIH NIH HHS
ID : R01 AT009268
Pays : United States
Informations de copyright
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
J Gerontol A Biol Sci Med Sci. 2013 Feb;68(2):168-74
pubmed: 22503991
Sci Adv. 2022 Mar 4;8(9):eabl9051
pubmed: 35235349
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1195-1209
pubmed: 31313502
Cell Death Differ. 2013 Jan;20(1):21-30
pubmed: 22722335
Age Ageing. 2013 Mar;42(2):203-9
pubmed: 23321202
Function (Oxf). 2021 May 10;2(4):zqab028
pubmed: 34124684
Cell Metab. 2021 Nov 2;33(11):2288-2300.e12
pubmed: 34525330
PLoS One. 2012;7(11):e50016
pubmed: 23166812
J Cell Biol. 2005 Nov 21;171(4):603-14
pubmed: 16286508
J Proteome Res. 2018 Nov 2;17(11):3740-3748
pubmed: 30265007
Cell Metab. 2013 May 7;17(5):731-44
pubmed: 23602450
Curr Opin Clin Nutr Metab Care. 2010 Jan;13(1):34-9
pubmed: 19898232
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1764-1775
pubmed: 34418329
Muscle Nerve. 2011 Sep;44(3):318-31
pubmed: 21949456
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17350-5
pubmed: 24082110
Biogerontology. 2013 Jun;14(3):303-23
pubmed: 23686362
Int J Cancer. 2012 Jun 1;130(11):2722-7
pubmed: 21796617
Endocrinol Metab (Seoul). 2020 Mar;35(1):1-6
pubmed: 32207258
STAR Protoc. 2021 Jun 23;2(3):100628
pubmed: 34235493
Diabetes Care. 2007 Jun;30(6):1507-12
pubmed: 17363749
J Physiol. 2018 Jan 1;596(1):83-103
pubmed: 29090454
J Appl Physiol (1985). 2021 Jul 1;131(1):72-82
pubmed: 34013745
Dev Cell. 2011 Sep 13;21(3):421-30
pubmed: 21889421
FASEB J. 2019 Nov;33(11):11735-11745
pubmed: 31361156
Cell. 1994 Sep 9;78(5):761-71
pubmed: 8087844
Skelet Muscle. 2011 May 04;1(1):21
pubmed: 21798099
Clin Nutr. 2010 Feb;29(1):18-23
pubmed: 19419806
Trends Cell Biol. 2014 Sep;24(9):506-14
pubmed: 24946960
Exp Gerontol. 2015 Apr;64:17-32
pubmed: 25681639
Mol Cell. 2013 Feb 7;49(3):411-21
pubmed: 23395271
Gerontology. 2009;55(5):550-8
pubmed: 19546513
Aging Cell. 2017 Jun;16(3):518-528
pubmed: 28371268
J Appl Physiol (1985). 2015 Mar 15;118(6):655-61
pubmed: 25593288
EMBO J. 2000 Jan 4;19(1):94-102
pubmed: 10619848
J Appl Physiol (1985). 2009 Oct;107(4):1172-80
pubmed: 19661454
J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):2076-2089
pubmed: 37448295
Geroscience. 2021 Feb;43(1):65-83
pubmed: 32588343
J Appl Physiol (1985). 2018 Jan 01;124(1):40-51
pubmed: 28982947
Front Neurosci. 2018 Feb 20;12:86
pubmed: 29515358
Bioengineering (Basel). 2021 Nov 01;8(11):
pubmed: 34821734
Aging (Albany NY). 2016 Jan;8(1):127-46
pubmed: 26826670